



ALK
Investor Relations Department
BÅge Alle 6-8
Horsholm DK-2970
Denmark

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

OMX: ALKB

| | |
|---------------|--|
| Last Trade: | 1018.00 |
| Trade Time: | 4:59 PM ET May 25, 2018 |
| Change: | 6.00 ▲ (+0.593%) |
| Day Range | 1006.00 - 1024.00 |
| 52-Week Range | 646.00 - 1081.00 |
| Volume | 1,026,900 |

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

ALK is the world leader in allergy vaccination (immunotherapy). It is the goal of ALK to increase the awareness of the company and its activities through a structured, ongoing, timely and balanced dialogue with investors, shareholders and other stakeholders. It is also a company goal to secure the liquidity of the company's shares and to generate reasonable, long-term returns to shareholders through share price increases and dividends.... [\(more\)](#)

Company releases [\[View all \]](#)

May 27, 2018
[Allergy experts: "Clinical effect of ALK's tree SLIT-tablet among the most significant ever seen in allergy immunotherapy trials"](#)

May 4, 2018
[Three-month interim report \(Q1\) 2018](#)

May 1, 2018
[Release date of three-month interim report \(Q1\) 2018 and audio cast](#)

Apr 17, 2018
[ALK's partner for Japan, Torii, secures pricing for new Japanese cedar SLIT-tablet](#)

Apr 11, 2018
[ALK announces allergy diagnostic partnership with Rellergen in China](#)

Upcoming Events [\[View all \]](#)

Aug 15, 2018
[Six-month interim report \(Q2\) 2018](#)

Nov 9, 2018
[Nine-month interim report \(Q3\) 2018](#)